Spruce Biosciences, Inc.

While it was technically successful, BridgeBio Pharma, Inc. ’s Phase I/II study of its gene therapy BBP-631 in congenital adrenal hyperplasia (CAH) did not quite deliver a strong enough result to jus

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial